Abstract:Microbiome signature ofNon-responder to Fecal Microbiota Transplantation in Patient with Steroid-refractory Chronic Graft-versus-host Disease after Hematopoietic Stem Cell Transplantation Introduction Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative treatment for patients with hematological malignancies. Chronic GVHD (cGVHD) is the major cause of morbidity and non-relapse mortality after allo-HCT and characterize by a chronic inflammatory disease involving T cell and B cell dysregulation. Emerging evidence showed that gastrointestinal dysbiosis and lack of microbe-derived metabolites are associated to cGVHD development. Several groups and our pilot study using fecal microbiota transplantation (FMT) from healthy donor to treat patients with steroid-refractory cGVHD (SR-cGVHD) has showed encouraging results. To characterize the pathogen by which predominant colonizing on non-responder after FMT therapy, we carried out 16s RNA sequence from non-responders' feces. Here, we report the preliminary results of 16s RNA sequence of the feces fromnon-responders after FMT. Method 12 patients aged 16-60 years with SR-cGVHD after allogenic hematopoietic cell transplantation (alloHCT) were enrolled. A total of 31 FMTs were performed via colonoscopy in 12 patients with SR-GVHD over three consecutive months. FMT courses could be repeated from the same or a different donor according to physician's discretion. To characterize the impact of the FMT on the gut microbiota, stool samples from recipients were collected the day before FMT treatment and 4 weeks after FMT treatment then carried out 16s rRNA sequencing. No response was defined as unable to taper steroid dose or need to increase or add immunosuppressor for controlling GVHD progression. Result Microbiota characterization at the genus level revealed significant differences between healthy donors and non-responders with SR-cGVHD, both before and after FMT (Figure A). At baseline, patients showed reduced Megamonas, Subdoligranulum, Prevotella, Fusicatenibacter and Collinsella as compared with donors. A significantly increased portion of Ruminococcus and Streptococcus was observed in non-responders before FMT. Intriguingly, non-responders showed significantly higher level of Ruminococcus in non-responder before FMT when compared to donors, and persistent Ruminococcus colonization as well as Streptococcus colonization were associated with poorly clinical outcome of FMT treatment (Figure B). Moreover, insufficient colonization of multiple probiotics, such as Megamonas, Faecalibacterium, Agathobacter and Fusicatenibacter are linked to FMT treatment outcome in patient with steroid-refractory cGVHD (Figure C). Conclusion The present study indicates that a microbial ecosystem which rich of Ruminococcus and Streptococcus and low abundance of Megamonas, Faecalibacterium, Agathobacter and Fusicatenibacte in non-responders to FMT in patient with SR-cGVHD after allo-HCT. Disclosures No relevant conflicts of interest to declare.

[Clinical study of 19 cases of steroid-refractory gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with fecal microbiota transplantation]

Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease with Fecal Microbiota Transplantation: A Pilot Study

Fecal Microbiota Transplantation for Grade IV Steroid Refractory GI-GvHD: Interim Results a Non-randomized, Open-label, Phase 1 Clinical Study

Safety and Efficacy of Fecal Microbiota Transplantation for Grade IV Steroid Refractory GI-GvHD Patients: Interim Results From FMT2017002 Trial

Fecal Microbiota Transplantation for Treating Steroid-Refractory Acute Graft-versus-Host Disease of the Gut

Microbiota Metabolite Short Chain Fatty Acid Acetate Promotes Intestinal IgA Response to Microbiota Which is Mediated by GPR43

Microbiome Signature Ofnon-Responder to Fecal Microbiota Transplantation in Patient with Steroid-Refractory Chronic Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation

Fecal microbiota transplantation in capsules for the treatment of steroid refractory and steroid dependent acute graft vs. host disease: a pilot study

Fecal Microbiota Transfer in Acute Graft-versus-Host Disease following Allogeneic Stem Cell Transplantation

IDDF2019-ABS-0157 Fecal Microbiota Transplantations Reconstitute Gut Fungal and Viral Microbiota in Graft-Versus-host Disease

Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD

The Clinical and Steroid-Free Remission of Fecal Microbiota Transplantation to Patients with Ulcerative Colitis: A Meta-Analysis

Elevated Plasma IL-22 Levels Correlated with Th1 and Th22 Cells in Patients with Immune Thrombocytopenia

Fecal Microbiota Transplantation Versus Glucocorticoids for the Induction of Remission in Mild to Moderate Ulcerative Colitis

Fecal Microbiota Transplantation Ameliorates Active Ulcerative Colitis by Downregulating Pro-inflammatory Cytokines in Mucosa and Serum

Longitudinal dynamics of gut bacteriome, mycobiome and virome after fecal microbiota transplantation in graft-versus-host disease

Ulcerative Colitis in Response to Fecal Microbiota Transplantation via Modulation of Gut Microbiota and Th17/Treg Cell Balance

Fecal Microbiota Transplantation is a Promising Switch Therapy for Patients with Prior Failure of Infliximab in Crohn’s Disease

Interplay Between the Intestinal Microbiota and Acute Graft-Versus-Host Disease: Experimental Evidence and Clinical Significance

Fecal transplantation alleviates acute liver injury in mice through regulating Treg/Th17 cytokines balance

Fecal microbiota transplantation for induction of remission in Crohn's disease: a systematic review and meta-analysis